Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Inc.’s Chief Medical Officer, Martina Flammer, M.D., reported a planned stock sale. On 02/05/2026 she sold 869 shares of Insmed common stock at $152.44 per share in a transaction coded as a sale. After this trade, she beneficially owned 83,243 shares directly.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she adopted on February 27, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio moves from day-to-day corporate developments.
A holder of common stock in a NASDAQ‑listed company has filed a Form 144 notice to sell 869 shares through Merrill Lynch, with an aggregate market value of $132,462. The filing states that 213,273,469 shares of this class were outstanding and lists an approximate sale date of February 5, 2026.
The securities to be sold were acquired on February 1, 2026 via stock plan activity from the issuer. The person filing, identified in recent sales as Martina Flammer, also sold multiple blocks of common shares between November 11, 2025 and February 3, 2026, with individual trades ranging from hundreds to tens of thousands of shares.
INSMED Inc.'s Chief Operating Officer Roger Adsett reported a routine sale of company stock in connection with equity compensation. On February 3, 2026, he sold 791 shares of common stock at a price of $156.17 per share. A footnote explains that the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, Adsett beneficially owned 106,810 shares of INSMED common stock directly.
Insmed Inc.'s Chief Financial Officer, Sara Bonstein, reported a small share sale under a Form 4 filing. On 02/03/2026, she sold 748 shares of Insmed common stock at a price of $156.34 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary sale. After this transaction, Bonstein beneficially owned 79,758 shares of Insmed common stock directly.
Insmed Inc. Chair and CEO William Lewis reported a routine share sale linked to tax withholding. On February 3, 2026, he sold 3,009 shares of common stock at $156.34 per share to satisfy tax obligations from vested restricted stock units and related broker fees. After this sale, he directly owned 303,882 shares of Insmed common stock. In addition, he had indirect beneficial ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSMED Inc's Chief Legal Officer reports a routine share sale related to equity compensation. On 02/03/2026, Michael Alexander Smith sold 640 shares of INSMED common stock at $156.27 per share. The filing explains the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. After this transaction, he directly beneficially owned 56,397 shares of common stock.
Insmed Inc.’s Chief Medical Officer Martina Flammer reported a series of stock transactions. On February 2, 2026, she exercised a stock option for 7,982 shares of common stock at $65.72 per share and sold multiple blocks of common stock under a Rule 10b5-1 trading plan, at weighted average prices including $152.06, $153.16, $154.56, $155.46 and $156.86 per share. On February 3, 2026, she sold 795 shares at $155.77 per share to satisfy tax withholding and related broker fees upon RSU vesting. After these transactions, she directly owned 84,112 shares of common stock and held 23,948 stock options.
Insmed common stockholder files notice to sell shares under Rule 144. The filing covers a planned sale of 791 common shares of Insmed through Merrill Lynch on the NASDAQ, with an aggregate market value of 123,526 and 213,273,469 shares outstanding.
The shares to be sold were acquired on 02/01/2026 via stock plan activity from the issuer. The notice also lists recent sales by Roger Adsett during January 2026, including 2,059 common shares for gross proceeds of 358,616, 802 shares for 140,406, and 1,429 shares for 247,688.
A shareholder of INSM has filed a notice under Rule 144 to sell 640 shares of common stock through Merrill Lynch on the NASDAQ, with an approximate sale date of 02/03/2026. The shares were acquired on 02/01/2026 via stock plan activity from the issuer.
The notice also lists earlier sales by Michael Smith over the past three months, including 27,130 common shares sold on 11/03/2025 for gross proceeds of 4,985,054, alongside several smaller sales in January 2026.
William Lewis filed a notice of proposed sale under Rule 144 to sell 3,009 shares of common stock through Merrill Lynch in Washington, DC. The shares are listed on NASDAQ, and the approximate sale date stated is February 3, 2026.
The shares to be sold were acquired on February 1, 2026 via stock plan activity from the issuer. Over the prior three months, William Lewis reported several other common stock sales, including blocks of 19,215 and 10,699 shares, with disclosed gross proceeds for each transaction.